van Dongen Jeanne E, Segerink Loes I
BIOS Lab on a Chip Group, MESA+ Institute for Nanotechnology, Technical Medical Centre, Max Planck Institute for Complex Fluid Dynamics, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.
ACS Synth Biol. 2025 Feb 21;14(2):323-331. doi: 10.1021/acssynbio.4c00816. Epub 2025 Jan 29.
Advancements in molecular diagnostics, such as polymerase chain reaction and next-generation sequencing, have revolutionized disease management and prognosis. Despite these advancements in molecular diagnostics, the field faces challenges due to high operational costs and the need for sophisticated equipment and highly trained personnel besides having several technical limitations. The emergent field of CRISPR/Cas sensing technology is showing promise as a new paradigm in clinical diagnostics, although widespread clinical adoption remains limited. This perspective paper discusses specific cases where CRISPR/Cas technology can surmount the challenges of existing diagnostic methods by stressing the significant role that CRISPR/Cas technology can play in revolutionizing clinical diagnostics. It underscores the urgency and importance of addressing the technological and regulatory hurdles that must be overcome to harness this technology effectively in clinical laboratories.
分子诊断技术的进步，如聚合酶链反应和下一代测序，已经彻底改变了疾病的管理和预后。尽管分子诊断技术取得了这些进展，但该领域仍面临挑战，因为除了存在一些技术限制外，其运营成本高昂，还需要精密设备和训练有素的人员。CRISPR/Cas传感技术这一新兴领域作为临床诊断的新范例显示出了前景，尽管其在临床上的广泛应用仍然有限。这篇观点论文讨论了CRISPR/Cas技术能够克服现有诊断方法挑战的具体案例，强调了CRISPR/Cas技术在彻底改变临床诊断方面可以发挥的重要作用。它强调了应对技术和监管障碍的紧迫性和重要性，这些障碍必须被克服，以便在临床实验室中有效利用这项技术。
